Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Pred... ( SAN FRANCISCO June 9 /- Halozyme ...)

HOME >> MEDICINE >> TECHNOLOGY

Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

Date:6/9/2008

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new Phase I data for the company's diabetes mellitus program at the American Diabetes Association's 68th Scientific Sessions. The data showed that combining the company's proprietary recombinant human hyaluronidase enzyme (rHuPH20) with Humulin R(R) (regular insulin human) or Humalog(R) (insulin lispro) yielded pharmacokinetics and glucodynamics that better mimicked physiologic prandial (mealtime) insulin release and activity than Humulin R or Humalog alone.

Key pharmacokinetic (PK) and glucodynamic (GD) improvements observed in the study include:
-- Significantly faster systemic absorption of each insulin, starting with

the first observation time point of three minutes after injection

-- Significantly faster and greater glucose lowering activity early after

injection

-- Significantly greater peak insulin levels for the same dose

administered

-- Significantly lower variability of key PK and GD variables across

subjects

-- rHuPH20 in combination with Humulin demonstrated statistically

significant improvement across all parameters when compared to Humalog

alone

By making mealtime insulins faster, i.e., shifting insulin exposure and glucose lowering activity to earlier times and away from late postprandial times, combination with rHuPH20 yielded a profile of insulin kinetics and activity more like that of natural, endogenous prandial insulin release.

Diabetes mellitus is an increasingly prevalent, costly condition associated
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD

Post Your Comments:

(Date:5/24/2013)... Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), a ... that Dr. Robert Grieve , the Company,s ... , executive vice president and chief financial officer, will ... being held May 30, 2013 in New York ... The Company,s presentation is scheduled to begin at 1:30 ...

(Date:5/24/2013)... 24, 2013 Sinovac Biotech Ltd. (NASDAQ: ... products in China , announced ... of Sinovac, obtained the Certificate of Good Manufacturing ... China State and Food Administration (CFDA) for its ... and its Changping filing and packaging facility. The ...

(Date:5/23/2013)... Inc. (Vanda) (NASDAQ: VNDA ) today announced that ... of the Year by the Tech Council of ... 25 th Annual Tech Awards Celebration held in ... the leaders and innovators in the technology and life science ... regions. "We are deeply honored to receive ...

Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2 Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2 Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3 Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2

[0] Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference [0] Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines [0] Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland

... -,Phytopharm plc (LSE: PYM) ("Phytopharm" or the ... reverses the,changes in the area of the ... be presented by Dr Jonathan Brotchie, an,internationally ... International Congress of Parkinson's Disease and Movement,Disorders' ...

... the Companies' Novel Heat Shock Protein 90 ... Biological,Activity , CAMBRIDGE, Mass. and GAITHERSBURG, Md., ... Inc. (Nasdaq:INFI) and,MedImmune, Inc. (Nasdaq:MEDI) today announced ... trial of the companies' heat shock,protein 90 ...

Cached Medicine Technology:Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 2 Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 3 Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 4 Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 5 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6 Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7

Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting

(Date:5/25/2013)... According to a new market ... published by MarketsandMarkets is expected to reach $544.02 ... which analyzes and studies the major market drivers, ... and Rest of the World. , Browse:, ... 87 Figures , 175 ...

(Date:5/25/2013)... Vancouver, BC (PRWEB) May 25, 2013 ... of the most beautiful and powerful women that ever ... was felt by some of the most powerful men ... used many beauty remedies to keep her skin glowing ... treatments made with bees- wax, maringa oil and cyprus ...

(Date:5/25/2013)... Los Angeles, CA (PRWEB) May 25, 2013 ... will grow at an average annual rate of 28.7% ... growth of 17.9% in 2013. From 2002 and 2008, no ... analyst Kevin Culbert, causing relatively modest growth during that period. ... (FDA) has approved six new products. This factor contributed to ...

(Date:5/25/2013)... 25, 2013 Ayurveda is the ... wisdom of life". While a medical science, its scope enters ... consciousness. Its fundamental philosophy is that disease is the end ... order to re-establish optimal health, one must discover where we ... style which brings us back into perfect harmony. , The ...

(Date:5/25/2013)... Flagstaff, Arizona (PRWEB) May 25, 2013 The ... Rehabilitation Center, their parents, and the B2B staff all came ... While everyone enjoyed an array of Indian Cuisine, the residents ... the company, for helping them on their road to recovery, ... started the Drug and Alcohol center in 2010 after realizing ...

Breaking Medicine News(10 mins):Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4 Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2 Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3 Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2 Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3 Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2 Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2

[0] Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets [0] The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician [0] Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld [0] Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California [0] Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary

... , WEDNESDAY, Nov. 2 (HealthDay News) -- A new drug ... to improved lung function and fewer symptoms in people with ... -- is the first to halt the underlying processes that ... build up in the lungs and the pancreas and can ...

... WEDNESDAY, Nov. 2 (HealthDay News) -- The death toll in ... farm has reached 29, with another 139 people sickened in ... recently that the outbreak appeared to have been caused by ... Sept. 22 and 23 by federal and state authorities at ...

... not effectively prepare firefighters for the range of ... human factors/ergonomics researchers Michael R. Baumann, Carol L. ... 2011 Human Factors article, "Phased Training ... the authors assess the value of current scenario-based ...

... , WEDNESDAY, Nov. 2 (HealthDay News) -- Researchers using ... far determined that it was a child of a wealthy ... The mummy, owned by the Spurlock Museum at ... 1990, and more scans with updated CT technology this year. ...

... (HealthDay News) -- The legalization of medical marijuana in ... the availability and appeal of the drug among youth, ... the study, Rhode Island Hospital researchers examined adolescent marijuana ... 2009. Rhode Island legalized medical marijuana in 2006. ...

... from the University of Notre Dame,s Keck Center ... are joining forces to use a new medical ... patients.Researchers at the Keck Center investigate how the ... inflammatory diseases like sepsis, atherosclerosis and asthma. In ...

Cached Medicine News:Health News:New Drug Targets Underlying Cause of Cystic Fibrosis 2 Health News:New Drug Targets Underlying Cause of Cystic Fibrosis 3 Health News:New Drug Targets Underlying Cause of Cystic Fibrosis 4 Health News:Death Toll From Listeria Outbreak Hits 29 2 Health News:Death Toll From Listeria Outbreak Hits 29 3 Health News:Current training programs may not prepare firefighters to combat stress 2 Health News:Modern Technology Reveals Clues From Egyptian Mummy 2 Health News:Univesity of Notre Dame researchers form new partnership to help trauma patients 2

New Drug Targets Underlying Cause of Cystic Fibrosis Death Toll From Listeria Outbreak Hits 29 Current training programs may not prepare firefighters to combat stress Modern Technology Reveals Clues From Egyptian Mummy Teen Pot Use Unaffected by Medical Marijuana Law: Study Univesity of Notre Dame researchers form new partnership to help trauma patients

High sensitive, specific one step immunochromatographic assay for human infectious disease...

Span Diagnostics Limited...

Malaria (P. fal.) Ag Rapid Test...

OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....

Medicine Products:

Malaria P.v. Ab Test Parahit f Malaria Dipstick/Device Malaria (P. fal.) Ag Rapid Test OptiMAL Malaria Test